Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns
Shots:
- The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555- 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients- and is sponsored by the NIAID
- Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the patients participating in the study. DSMB also considered the impact of the ACTIV-3 study pause on ACTIV-2 and did not recommend any changes to that study’s design or enrollment
- Lilly is testing both single Ab therapy- as well as combinations of Abs as potential therapeutics for COVID-19- across two different patient populations in P-II BLAZE-1- P-III BLAZE-2- and ACTIV-2 study. These trials are not affected by the enrollment pause in the ACTIV-3 clinical trial
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com